Intellia Therapeutics (NTLA)
(Real Time Quote from BATS)
$23.32 USD
+0.07 (0.30%)
Updated Jun 5, 2024 01:42 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Intellia Therapeutics, Inc. [NTLA]
Reports for Purchase
Showing records 101 - 120 ( 281 total )
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia''s First Ex Vivo Clinical Program, NTLA-5001 Kicks Into High Gear; First AML Patient Dosed in Phase 1/2a Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Dose-Dependent Pathogenic Serum Protein Reduction with ATTR Therapy
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Results; Additional Readout for ATTRv-PN; In Vivo Development Candidate for AATD; Broadening Cell Therapy Program
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q21: Additional Data From Lead Program on Feb 28th
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia and ONK Therapeutics Join Forces to Develop Allogeneic CRISPR-Edited NK Cell Therapies
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Twin Studies Published in Science Translational Medicine Support Efficacy of Targeting WT-1 Epitopes in Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia Acquires Rewrite Therapeutics, Expanding its Formidable Arsenal of Genome Editing Tools
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia Provides Updates on Strategic Priorities and Development Milestones for 2022; Sets Stage for Catalyst Rich-Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia Forms Strategic Partnership With Kyverna to Tackle B Cell-Mediated Autoimmune Diseases
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M